dna-strand.jpgIPNews® – La Jolla Pharmaceutical Company was granted Patent Number 8,187,642 by the U.S. Patent and Trademark Office for compositions of modified pectins. 

This is the third patent by La Jolla Pharmaceutical that attempts to develop a reduction in the growth rate of cancer.  The company is attempting to develop innovative therapies using the galectin family of proteins.  To continue reading, click: La Jolla Pharmaceutical Nabs Patent